Platelet-function testing in patients undergoing neurovascular procedures: Caught between a rock and a hard place

American Journal of Neuroradiology

Volumn 34, Issue 4, 2013, Pages 730-734

  Comin, J ^b   Kallmes, D F ^a  

^a MAYO CLINIC   (United States)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASUGREL; PROTON PUMP; TICAGRELOR; TICLOPIDINE;

ADVERSE OUTCOME; ARTICLE; ATHEROSCLEROSIS; BLEEDING; CLINICAL TRIAL (TOPIC); CORONARY STENT; DRUG MECHANISM; DRUG POTENTIATION; ENDOVASCULAR SURGERY; HUMAN; ISCHEMIA; NEURORADIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; RISK FACTOR; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOEMBOLISM; THROMBOSIS; TREATMENT RESPONSE;

CEREBRAL HEMORRHAGE; DRUG RESISTANCE; ENDOVASCULAR PROCEDURES; FEMALE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; STENTS; THROMBOEMBOLISM; TICLOPIDINE;

EID: 84876706251     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3440     Document Type: Article

References (49)

1. Goh C, Churilov L, Mitchell P, et al. Clopidogrel hyper-response and bleeding risk in neurointerventional procedures. AJNR Am J Neuroradiol 2013;34:721-26
2. Fifi JT, Brockington C, Narang J, et al. Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting. AJNR Am J Neuroradiol 2013;34:716-20
3. Combescure C, Fontana P, Mallouk N, et al. Clinical implications of clopidogrel non-response in cardiovascular patients: A systematic review and meta-analysis. J Thromb Haemost 2010;8:923-33
4. Breet N, van Werkum J, Bouman H, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754-62
5. Gurbel P, Bliden K, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST study. J Am Coll Cardiol 2005;46:1827-32 (Pubitemid 41579803)
6. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30 (Pubitemid 40617065)
7. Ajzenberg N, Aubry P, Huisse M, et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: A case-control study. JAmColl Cardiol 2005;45:1753-56 (Pubitemid 40779851)
8. Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel nonresponders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89: 783-87 (Pubitemid 36603418)
9. Blindt R, Stellbrink K, de Taeye A, et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007;98:1329-34 (Pubitemid 350239106)
10. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312-17 (Pubitemid 46891710)
11. Price M, Endemann S, Gollapudi R, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008;29:992-1000 (Pubitemid 351844676)
12. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53:849-56
13. Marcucci R, Gori A, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay. Circulation 2009;119:237-42
14. Price M, Berger P, Teirstein P, et al. Standard vs high dose clopidogrel based on platelet function testing after percutaneous coronary intervention. JAMA 2011;305:1097-105
15. Muller-Schunk S, Linn J, Peters N, et al. Monitoring of clopidogrelrelated platelet inhibition: Correlation of nonresponse with clinical outcome in supra-aortic stenting. AJNR Am J Neuroradiol 2008;29:786-91 (Pubitemid 351571565)
16. Depta J, Fowler J, Novak E, et al. Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack. Stroke 2012;43: 2376-81
17. Gawaz M, Neumann F, Ott I, et al. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996;93:229-37 (Pubitemid 26031479)
18. Angiolillo D, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54:2430-35 (Pubitemid 41134272)
19. Goto S, Sakai H, Goto M, et al. Enhanced shear-induced platelet aggregation in acute myocardial infarction. Circulation 1999; 99:608-13 (Pubitemid 29077358)
20. Angiolillo D, Costa M, Shoemaker S, et al. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. Am J Cardiol 2008;101: 440-45 (Pubitemid 351210628)
21. Aleil B, Jacquemin L, De Poli F, et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: Results from the VASP-02 randomized study. JACC Cardiovasc Interv 2008;1:631-38
22. Matetzky S, Fefer P, Shenkman B, et al. Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction. Am J Cardiol 2008;102:524-29
23. Brandt J, Payne C, Wiviott S, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:66.e9-16
24. Jeong Y, Lee S, Choi B, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: Results of the ACCELRESISTANCE randomized study. J Am Coll Cardiol 2009;53: 1101-09
25. Angiolillo D, Capranzano P, Goto S, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: Results of the OPTIMUS-2 study. Eur Heart J 2008;29:2202-11
26. Campo G, Vagimigli M, Gemmati D, et al. Poor responsiveness to clopidogrel: Drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study. JAmColl Cardiol 2007;50:1132-37 (Pubitemid 47375009)
27. Gurbel P, Bliden K, Antonino M, et al. Abstract 5901: The effect of ticagrelor in stable coronary artery disease patients non responsive to clopidogrel: The RESPOND study. Circulation 2009;120:S1173
28. Valgimigli M, Campo G, de Cesare N, et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: Results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study. Circulation 2009;119: 3215-22
29. Cuisset T, Frere C, Quilici J, et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: A prospective, randomized study. JACC Cardiovasc Interv 2008;1:649-53
30. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decreased rate of major adverse cardiovascular events in patients with clopidogrel resistance. J Am Coll Cardiol 2008;51:1404-11 (Pubitemid 351447314)
31. Wood S. TRIGGER-PCI halted: Low events stymie plateletreactivity trial with prasugrel, clopidogrel. www.theheart.org/article/1200057.do. Accessed December 6, 2012
32. Siller-Matula J, Francesconi M, Dechant C, et al. Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study. Int J Cardiol 2012 May 30 [Epub ahead of print]
33. Aradi D, Rideg O, Vorobcsuk A, et al. Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity. Eur J Clin Invest 2012;42:384-92
34. Ari H, Ozkan H, Karacinar A, et al. The EFFect of hIgh-dose Clop-Idogrel treatmENT in patients with clopidogrel resistance (The EFFICIENT Trial). Int J Cardiol 2012;157:374-80
35. Wang X, Zhang D, Zhuang S, et al. Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. Clin Cardiol 2011;34:332-38
36. Hazarbasanov D, Velchev V, Finkov B, et al. Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. J Thromb Thrombolysis 2012;34:85-90
37. Aradi D, Komocsi A, Price M, et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. Int J Cardiol 2012 Jun 15 [Epub ahead of print]
38. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study. Circulation 2005;111: 2099-106 (Pubitemid 40577905)
39. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006;48:931-38 (Pubitemid 44292463)
40. Mehta S, Tanquay, Eikelboom J, et al. Double-dose versus standarddose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomized factorial trial. Lancet 2010;376:1233-43
41. Wiviott S, Braunwald E, McCabe C, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15 (Pubitemid 350106708)
42. Trenk D, Stone G, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: Results of the TRIGGER-PCI study. J Am Coll Cardiol 2012;59:2159-64
43. Capranzano P, Tamburino C, Capodanno D, et al. Platelet function profiles in the elderly: Results of a pharmacodynamics study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. Thromb Haemost 2011;106:1149-57
44. Dalén M, van der Linden J, Lindwall G, et al. Correlation between point-of-care platelet function testing and bleeding after coronary artery surgery. Scand Cardiovasc J 2012;46:32-38
45. Wallentin L, Becker R, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361: 1045-57
46. Angiolillo D, Schneider D, Bhatt D, et al. Pharmacodynamic effects of cangrelor and clopidogrel: The platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis 2012;34:44-55
47. Lee S, Park S, Hong M, et al. Triple versus dual antiplatelet therapy after coronary stenting: Impact on stent thrombosis. J AmColl Cardiol 2005;46:1833-37 (Pubitemid 41579804)
48. Toma C, Zahr F, Moquilanski D, et al. Impact of anemia on platelet response to clopidogrel in patients undergoing percutaneous coronary stenting. Am J Cardiol 2012;109:1148-53
49. Gaglia M, Torguson R, Pakala R, et al. Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention. J Interv Cardiol 2011;24:529-34